We believe you are vital to deliver this impact
The year 2020 presented us with major challenges. We are happy to announce that we obtained freedom-to-operate in Europe for the first multiplex assay to classify breast cancer. Ongoing projects include analysis of FFPE biopsies, xenograft classification, exosome research and many more.
Join us in our mission:
- An RUO molecular classification of breast cancer is now approved for sale in Europe.
- Our R&D embarked on setting up sensitive techniques to measure biomarkers in blood-derived exosomes.
- Our professional team is seeking partnerships to enhance market entry and develop new products.
- Our commercial team is providing high quality reagents for research institutions, included cutting edge technologies and services.
JOIN US and SUBSCRIBE below for more information on assay performance, product pipeline and applications.
Product Development and Projects
M3 Profiler
To synergise the advantages of microfluidics, and multiplex bead based assays, to measure biomarkers in blood-derived exosomes
Cov-plex
To develop a molecular test that measures COVID-19 (SARS-CoV-2) immune response for vaccine surveillance.
Bookind
To innovate a companion diagnostic product that predicts use of specific therapeutics in Epilepsy.
